ClinicalTrials.gg
CompletedNCT01981616Updated Jul 21, 2014Results posted

Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab

A Phase 1 interventional study of Vedolizumab and Placebo in Inflammatory Bowel Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Inflammatory Bowel Diseases by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Inflammatory Bowel Diseases · Takeda.

Started
2011
the only one that year
Phase 1
Only one
of the 24
Registered
2nd of 24
by date

Among the 24 studies in Inflammatory Bowel Diseases by Takeda, this one is the only one that started in 2011, is the only one in phase 1, and was the 2nd registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

1 of the 24 studies in Inflammatory Bowel Diseases by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Inflammatory Bowel Diseases by Takeda, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the rates of seroconversion to a hepatitis B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo. Secondary objectives are to determine the rates of seroconversion to an oral cholera vaccine series, assess change in anti-hepatitis B surface antibodies and assess the safety and tolerability of a single 750-mg IV dose of vedolizumab.

03

Conditions studied

  • Inflammatory Bowel Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 18 to 39 years of age.
  2. (BMI) between 18 and 32 kg/m\^2, inclusive.
  3. Females who: are for at least 1 year before the Screening visit, OR; are surgically sterile, OR; if they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
  4. Males, even if surgically sterilized (ie, status postvasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or; agree to completely abstain from heterosexual intercourse.
  5. Is willing and able to provide written informed consent and to comply with all study requirements.
  6. Has suitable venous access for the study-required infusions and blood samples.

Exclusion criteria

Exclusion criteria

  1. Known exposure to virus.
  2. Known prior hepatitis B vaccination, irrespective of number of doses received, or any previous employment in a healthcare setting.
  3. Seropositivity for prior hepatitis B infection or hepatitis B vaccination during the Screening period.
  4. Known exposure to cholera or prior Dukoral exposure, irrespective of number of doses received.
  5. History of major cardiovascular, pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, immunological, psychiatric, or other major medical disorder.
  6. History of any major neurological disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease, or any neurological disorders that would confound neurological examination, or results of the subjective or objective progressive multifocal leukoencephalopathy (PML) checklist during the study.
  7. Any history of coagulation disorders, or history or current use of anticoagulation therapy (eg, warfarin, heparin).
  8. Any disorder that requires chronic or regular use of any form of (including but not limited to topical, intranasal, rectal, etc), immunomodulator (eg, azathioprine) therapy, or other (eg, mycophenolate, tacrolimus, tumor necrosis factor-alpha (TNF-α) antagonist).
  9. Regular use of herbal, homeopathic or natural supplements including but not limited to putative immune stimulants. Participants must not have used any of these agents within 30 days of enrollment.
  10. Female participants who are lactating or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 predose; women considering becoming pregnant while on study are to be excluded.
  11. Acute illness within the preceding 30 days that, in the opinion of the investigator, could pose a threat or harm to the participant or obscure laboratory test results or interpretation of data on exposure to vedolizumab (eg, mononucleosis).
  12. Any history of , except for the following: (a) adequately-treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to enrollment; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years before enrollment.
  13. Had a surgical procedure requiring general anesthesia within 30 days before the initial Screening visit or is planning to undergo a surgery that requires general anesthesia during the study period. Minor surgeries that are medically necessary and that do not require general anesthesia may be allowable during the study period.
  14. One or more positive responses on the PML subjective symptom checklist at screening or before dosing on Day 1.
  15. Blood donation within 60 days before screening.
  16. Unable to attend all study days or comply with protocol requirements.
  17. Any other reason that, in the opinion of the investigator, would confound the conduct of this study or the interpretation of the results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Vedolizumab 750 mg

    Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.

    Drug: Vedolizumab · Biological: Hepatitis B vaccine · Biological: Oral cholera vaccine

  • Placebo comparator
    Placebo

    Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.

    Drug: Placebo · Biological: Hepatitis B vaccine · Biological: Oral cholera vaccine

Interventions

  • Vedolizumab for intravenous infusion

    Also known as: Entyvio, MLN0002, MLN02, LDP-02

  • DrugPlacebo

    Placebo intravenous infusion

  • BiologicalHepatitis B vaccine

    Also known as: HBVAXPRO

  • BiologicalOral cholera vaccine

    Also known as: Dukoral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74

    Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.

    Time frame: Day 74

Secondary outcomes

  1. Percentage of Participants With an Immune Response to Oral Cholera Vaccine

    A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.

    Time frame: Baseline and Day 74

  2. Anti-Hepatitis B Surface Antibody Over Time

    Time frame: Baseline and Days 18, 32, 60 and 74

  3. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.

    Time frame: From the first dose of study medication through Day 127

07

Results

Posted Jul 21, 2014

Participant flow

Participants took part in the study at one investigative site in the United Kingdom from 13 September 2011 to 13 July 2012.

Participant flow — Overall Study
MilestoneVedolizumab 750 mgPlacebo
Started6463
Completed6362
Not completed11
Withdrew: Adverse event01
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74

Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.

Time frame:
Day 74
Reported as:
Number · percentage of participants
Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74
percentage of participantsVedolizumab 750 mgPlacebo
Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 7488.5 (80.5 to 96.5)90.3 (83.0 to 97.7)
Statistical analysis
  • Vedolizumab 750 mg vs Placebo · Difference from placebo: -1.8 · 95% CI -12.7 to 9.1
SecondaryPercentage of Participants With an Immune Response to Oral Cholera Vaccine

A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.

Time frame:
Baseline and Day 74
Reported as:
Number · percentage of participants
Percentage of Participants With an Immune Response to Oral Cholera Vaccine
percentage of participantsVedolizumab 750 mgPlacebo
Percentage of Participants With an Immune Response to Oral Cholera Vaccine82.5 (73.2 to 91.9)96.8 (92.4 to 100.0)
Statistical analysis
  • Vedolizumab 750 mg vs Placebo · Difference from placebo: -14.2 · 95% CI -24.6 to -3.9
SecondaryAnti-Hepatitis B Surface Antibody Over Time
Time frame:
Baseline and Days 18, 32, 60 and 74
Reported as:
Geometric mean · IU/L
Anti-Hepatitis B Surface Antibody Over Time
IU/LVedolizumab 750 mgPlacebo
Baseline (n=24, 31)1.2 ± 51.91.0 ± 12.5
Day 18 (n=39, 40)2.5 ± 501.01.3 ± 73.5
Day 32 (n=37, 41)2.3 ± 472.81.6 ± 99.9
Day 60 (n=58, 59)16.3 ± 501.315.2 ± 365.8
Day 74 (n=59, 62)129.6 ± 359.3114.4 ± 539.6
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.

Time frame:
From the first dose of study medication through Day 127
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsVedolizumab 750 mgPlacebo
Any adverse event4150
Drug-related adverse event2222
Adverse event resulting in study discontinuation01
Serious adverse event01
Serious infection adverse events00
Drug-related serious adverse event00
Serious adverse event resulting in discontinuation00
Deaths00

Adverse events

Collected over From the first dose of study medication through Day 127.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 750 mg—0/64 (0%)24/64 (37.5%)
Placebo—1/63 (1.6%)25/63 (39.7%)
Most frequent serious events
Most frequent serious events
EventVedolizumab 750 mgPlacebo
Spontaneous abortionPregnancy, puerperium and perinatal conditions0/641/63
Most frequent other events
Most frequent other events
EventVedolizumab 750 mgPlacebo
HeadacheNervous system disorders12/648/63
Viral upper respiratory tract infectionInfections and infestations8/648/63
GastroenteritisInfections and infestations2/645/63
FatigueGeneral disorders1/644/63
Upper respiratory tract infectionInfections and infestations4/643/63
NauseaGastrointestinal disorders4/640/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vedolizumab 750 mgPlaceboTotal
Mean27.7 ± 5.6427.3 ± 5.3327.5 ± 5.47
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 750 mgPlaceboTotal
Female202040
Male444387
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vedolizumab 750 mgPlaceboTotal
White6256118
Black112
Asian123
Other044
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vedolizumab 750 mgPlaceboTotal
Hispanic or Latino011
Not Hispanic or Latino6462126
Region of Enrollment
Region of Enrollment(participants)Vedolizumab 750 mgPlaceboTotal
United Kingdom6463127
Height
Height(cm)Vedolizumab 750 mgPlaceboTotal
Mean173.4 ± 8.89173.1 ± 7.94173.3 ± 8.40
Weight
Weight(kg)Vedolizumab 750 mgPlaceboTotal
Mean75.0 ± 13.4876.2 ± 11.5375.6 ± 12.51
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vedolizumab 750 mgPlaceboTotal
Mean24.8 ± 3.3425.4 ± 2.7125.1 ± 3.04
08

Study locations

1 site
  • ICON Development Solutions
    Manchester, United Kingdom
09

References and documents

Publications

  • Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015 Jan;64(1):77-83. doi: 10.1136/gutjnl-2014-307127. Epub 2014 Apr 24. PubMed 24763133 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2013
First posted
Nov 11, 2013
Start
Sep 2011
Primary completionActual
May 2012
CompletionActual
Jul 2012
Results first posted
Jul 21, 2014
Last update
Jul 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01981616
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Sep 2011
Primary completion
May 2012
Completion
Jul 2012
Results posted
Jul 21, 2014
Last update
Jul 21, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion